Over 100 Companies Drive NSCLC Clinical Trial Boom with Targeted Therapies and Precision Medicine Approaches

Over 100 companies are actively working on the non-small cell lung cancer (NSCLC) clinical trial pipeline, with over 120 therapies in various stages of development. Major pharmaceutical companies such as Merck Sharp & Dohme LLC, AbbVie, and Exelixis are evaluating new treatments to improve the treatment landscape for NSCLC. Promising pipeline therapies like V940, Telisotuzumab Vedotin, and QL1706 are under clinical trials.

The non-small cell lung cancer (NSCLC) clinical trial pipeline is witnessing significant activity, with over 100 companies actively engaged in developing over 120 therapies at various stages of development [1]. Major pharmaceutical giants like Merck Sharp & Dohme LLC, AbbVie, and Exelixis are among the key players spearheading this effort [1].

The surge in NSCLC diagnoses, with a global prevalence of 32.3% among NSCLC patients [1], has fueled the demand for innovative treatments and personalized medicine approaches. This, in turn, has led to increased investment in research, technological advancements, and healthcare infrastructure, expanding market opportunities worldwide.

Some of the promising pipeline therapies under clinical trials include V940, Telisotuzumab Vedotin, and QL1706 [1]. V940, developed by Cullinan Oncology, is a potential first-in-class, oral, and potent small molecule inhibitor of the EGFRvIII oncogene [1]. Telisotuzumab Vedotin, from Suzhou Puhe Pharmaceutical Technology, is an antibody-drug conjugate targeting the Trop-2 antigen, which is overexpressed in various solid tumors, including NSCLC [1]. QL1706, developed by Taiho Pharmaceutical, is a novel, oral, and highly selective small molecule inhibitor of the EGFRvIII oncogene [1].

Other notable companies, such as ORIC Pharmaceuticals, Nuvalent, Shanghai Junshi Biosciences, Janux Therapeutics, HK inno.N, Betta Pharmaceuticals, Bridge Biotherapeutics, Sorrento Therapeutics, Bayer, Avistone Pharmaceuticals, and more, are also working on developing novel EGFR non-small cell lung cancer drugs to improve the treatment landscape [1].

In summary, the non-small cell lung cancer clinical trial pipeline is robust, with over 100 companies actively engaged in developing over 120 therapies. Key players like Merck Sharp & Dohme LLC, AbbVie, and Exelixis are leading this effort, with promising pipeline therapies like V940, Telisotuzumab Vedotin, and QL1706 under clinical trials.

References:
[1] GlobeNewswire. EGFR Non-Small Cell Lung Cancer Clinical Trial Pipeline Appears Robust With 37+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight. July 03, 2024. https://www.globenewswire.com/news-release/2024/07/03/2908344/0/en/EGFR-Non-Small-Cell-Lung-Cancer-Clinical-Trial-Pipeline-Appears-Robust-With-37-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight.html